- Home
- RRGB vs STTK Comparison
RRGB vs STTK Comparison
Compare RRGB & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRGB
- STTK
- Stock Information
- Founded
- RRGB 1969
- STTK 2016
- Country
- RRGB United States
- STTK United States
- Employees
- RRGB N/A
- STTK N/A
- Industry
- RRGB Restaurants
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- RRGB Consumer Discretionary
- STTK Health Care
- Exchange
- RRGB Nasdaq
- STTK Nasdaq
- Market Cap
- RRGB 88.7M
- STTK 83.8M
- IPO Year
- RRGB 2002
- STTK 2020
- Fundamental
- Price
- RRGB $6.81
- STTK $2.14
- Analyst Decision
- RRGB Strong Buy
- STTK Hold
- Analyst Count
- RRGB 2
- STTK 6
- Target Price
- RRGB $11.00
- STTK $2.67
- AVG Volume (30 Days)
- RRGB 259.8K
- STTK 1.5M
- Earning Date
- RRGB 11-05-2025
- STTK 11-13-2025
- Dividend Yield
- RRGB N/A
- STTK N/A
- EPS Growth
- RRGB N/A
- STTK N/A
- EPS
- RRGB N/A
- STTK N/A
- Revenue
- RRGB $1,235,920,000.00
- STTK $2,997,000.00
- Revenue This Year
- RRGB N/A
- STTK N/A
- Revenue Next Year
- RRGB N/A
- STTK N/A
- P/E Ratio
- RRGB N/A
- STTK N/A
- Revenue Growth
- RRGB N/A
- STTK N/A
- 52 Week Low
- RRGB $2.50
- STTK $0.69
- 52 Week High
- RRGB $7.89
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- RRGB 61.14
- STTK 58.93
- Support Level
- RRGB $5.98
- STTK N/A
- Resistance Level
- RRGB $7.01
- STTK $2.01
- Average True Range (ATR)
- RRGB 0.27
- STTK 0.21
- MACD
- RRGB 0.04
- STTK 0.01
- Stochastic Oscillator
- RRGB 80.58
- STTK 99.53
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. The company has one operating and one reportable segment: restaurants.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.